Palivizumab in congenital heart disease: should international guidelines be revised?

Geskey, Joseph M

Palivizumab in congenital heart disease: should international guidelines be revised? [electronic resource] - Expert opinion on biological therapy Nov 2007 - 1615-20 p. digital

Publication Type: Editorial

1744-7682

10.1517/14712598.7.11.1615 doi


Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Antiviral Agents--therapeutic use
Child
Heart Defects, Congenital--drug therapy
Humans
International Cooperation
Palivizumab
Practice Guidelines as Topic
Respiratory Syncytial Virus Infections--drug therapy